Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ya the signs are all there...
"Increased interest of the large pharmaceutical companies in acquisition of pipeline at each stage in the development and trials process has generated a very active market for early stage compounds that have shown promise in bench and animal tests. Treatment of cancer by non-toxic methods of inhibiting the action of PKCalpha has become an area of specific interest. We believe that PharmaGap has established a novel method for selection and inhibition of PKCalpha which matches well with the focus of research in a number of potential licensees or purchasers," Mr. McInnis said.
discussions with four of the top 10 such companies and with one of the world's leading biotech companies have provided specifics of data required by potential licensees, which in turn contributed to the design of the tests that are about to begin," Mr. McInnis concluded.
Now that the tests have been completed we should see a Big Pharma Company do a deal with GAP
I bet it won't be long
Repeat of Jan-Mar 2002 coming
huge pop - settle out - gap up and run
Waiting for the deal with a pharma company,in talks
Waiting will pay here, got some traders .36
Sure it could but that is years away.If they can do a deal with a big Pharma Company like Merck the stock will be a monster overnight but thats if.
Should get more results soon according too the News Release on the 17
Red,
whats your target here iyo or where can this go iyo ? over $20?
tia
Don't think thats the case,still think those who bought high are just bailing it out here
So if you had new shares coming in to hold the price down that average would be alot lower
i'm guessing(but its close at least 28 mil traded over 50
54 mil since the 17 and 54 mil traded average price .53
Most of the shares bought over .50 were on the 17th
We have traded over twice that many shares since then
Naw the guys that bought high are dumping at loses now
looks to me like a cleverly controlled release
keep the market forces at bay while a plan is devised
Back in GAP here as i'm trying too get alot of freebees too hold
Major Implications For Cancer ?
Microcaps (and penny stocks in general) can be both exciting and very frustrating. While volatility seems to be the norm, every decade we also see something astonishing come out of a few of these small companies. Astonishing may mean a stock like Bre-X that starts out near 0.40 and ends up near $300 before someone is thrown out of a helicopter. Or it may mean honest discoveries like Diamet that went from penny status to a diamond mine worth Billions, Diamond Fields massive nickel discovery at Voisey Bay, Arequipa's gold discovery and buyout by Barrick in Peru. There are several more like this and likewise for the oil & gas industry.
The interesting part of all this, is that these are resource stocks. Success stories in the tech space we watched in 1999 and 2000 thanks to irrational exhuberance and an overheated market - although some amazing stories came out of that era like Research in Motion and their Blackberry which drove the price from under $3 to well over $100 now.
While all this is the stuff dreams are made of from a financial point of view, they did nothing to contribute to the betterment of mankind. Unless of course you count the Blackberry which for some is as critical as an oxygen tank attached to an emphysema patient ! And by betterment I mean contributing to our quality of life, not buying a new Lexus because your stock just went from a dollar to twenty.
So that brings us to the Biotech sector. From a microcap perspective, its often very difficult for these little companies to raise capital and as such, you rarely hear about major discoveries coming out of this field of science. Thanks to heavy regulation, they can take years to mature and if something significant does comes along, the majors typically buy them out before a massive double digit run in share price can occur. I've been buying penny stocks for over twenty years now and while I'm sure I've forgotten something by now, I cannot remember a huge biotech story coming out of Canada (from a small or microcap perspective).
That brings us to PharmaGap (GAP.V $0.35)
www.pharmagap.com
First and foremost. My introduction above is not meant to indicate this is the next retirement income plan. It simply demonstrates the potential of microcap stocks and proves that while its very difficult hitting a home run on these stocks, its also possible.
I typically don't bother with biotechs because very few ever amount to anything before they run out of cash, and I don't have the patience to sit on a penny stock for three years waiting for a miracle to occur. In addition to this, you need a very strong stomach for volatility. Pharmagap is a perfect example as it gained 450% in 1 day after running from $0.20 to $1.10 on April 17th as millions of dollars worth of buying piled into this stock. Yet you see the price now.
The morning of the 17th we sent GAP to our paid subscribers once a very important news release was issued. While everyone watched this incredible rise in price, we've now watched that same stock get destroyed from its high. The problem can be summed up in one word... traders. A tremendous amount of buying came into this company on news I will highlight below but with little happening in this market for the technical traders, it didn't take long for the gains and volume to pop onto the TSX.V radar. If momentum is positive, the trend remains intact. If the tide turns, so does the share price. As the price fell, the traders moved out and those who bought for a longer term hold likely second guessed their decision and cut a quick loss. People typically read into a trading pattern following news and use this to try and determine whether their assesment was right or wrong.
What all this "may" have done, is create a new opportunity for others. Had this stock not fallen back so hard I would have waited a long time before introducing it to free subscribers or on Stockhouse - the risks were just way too high. Even right now, the risks may be very high. This stock rarely ever traded prior to this news and the last few financings were done at $0.06 by the CEO. Unfortunately this company was so low on anyone's radar that the price and volume were ridiculously low.
World Class Management & Researchers
It was also this very same reason I (at first) totally ignored the news release I saw on April 17th. I honestly thought that in typical penny stock fashion it was nothing more than hype to help some slimey promoter get his stock off. It wasn't until I quickly did more research and found out this company was a spinoff from the National Research Council of Canada (Canada’s premier biological research organization) and the scientists behind this company were (surprisingly) amongst the best in their field. In addition to the scientific side, they have tremendous talent on the other side of the equation. As an example, their Chief Operating Officer was Vice President, Investment Banking with Credit Suisse First Boston in New York and TD Securities in New York and Toronto. This quickly ruled out the slimey promoter theory and immediately provided credibility.
Why the Excitement ?
In early trials on mice (announced April 17th), they treated a control group that resulted in tumours disappearing in 4 of the 5 with the 5th having enough damage to the tumour it could be easily broken down. In all other control groups (including chemo), there was no impact and the tumours would have resulted in death. What was amazing, this result was on a cancer type that accounts for 30% of all breast cancer with NO known treatment. Basically it moves so fact (typically to the lungs) that the patience dies in a short period of time.
In addition to this, they had excellent results on colon cancer treatment as well. Its this impact on the breast cancer tumours that is amazing however. If this continues and can be proven safe for humans, it "may" become a major breakthrough in cancer treatment.
The Memorial Sloan-Kettering Cancer Institute New York
www.mskcc.org
In an independent validation of GAP's potential, the company announced on April 24th they were partnering with The Memorial Sloan-Kettering Cancer Institute of New York - one of the world's premier cancer centers. This is over and above the research being done on breast cancer mentioned above. The Institute will be working with the company to develop a selective inhibitor of PKC theta for use in treatment of sarcomas, cancers of supportive and connective tissue (that is bone, cartilage, fat, muscle and blood vessels).
Said Sloan-Kettering's Dr. Schwartz: "I look forward to continuing my collaboration with PharmaGap for this exciting new compound, as it holds the promise of new treatment alternatives in the future for sarcoma patients. Selectively targeting PKC theta may provide therapeutic benefits not provided by current treatments."
Protein Kinase C (PKC)
Over the ages, experimental biology has used two research approaches, in vitro (within the glass) and in vivo (within the living). Typically drug candidate selection and experimentation occur at the simpler “test tube” level. The final proving ground is at the living level of Mice and Men and clinical trials.
Enter the Brave New World of computer biologists and their approach – in silico (within the silicon chip) where computer simulations model natural and laboratory processes.
PharmaGap is on the leading edge of in silico drug development. Their primary candidate, PhG-alpha-1, is one of a new breed of targeted cancer drugs that largely confine their activities to the tumor cells. Consider the huge benefit of hitting the target with a bullet compared to standard “shotgun” chemotherapies, where the hope is that they kill the cancer before they kill the patient.
PharmaGap’s current research centers on a family of naturally occurring enzymes known as Protein Kinase C (PKC). These enzymes have diverse and important effects on our cells. They must be highly regulated or controlled to maintain certain aspects of that delicate balance known as health. Numerous cancers involve over expression of PKC – too much of a good thing.
One member of the PKC family is especially noteworthy in the cancer realm – PKC alpha, which is the selected target for the PhG-alpha-1 drug.
Besides targeting, another very positive angle for PhG-alpha-1 relates to an unfortunate characteristic of many cases of cancer – Multi Drug Resistance or MDR. Special proteins embedded in the cell membrane, called MDR pumps, actually “spit out” any chemotherapy drug that enters the cancer cell – great for survival of the cancer cell, but certainly not the patient. There is a strong correlation between high levels of PKC and MDR activity. Perhaps PhG-alpha-1 could be a stone that kills two birds at once. The strategy of combining PhG-alpha-1 with other chemotherapeutic agents may open up a wider range of possibilities.
The area of PKC research is receiving much attention these days, and for good reason. Other members of the PKC family are implicated in such disorders as diabetes, cardiac disease, and Alzheimer’s. PhamaGap recently announced they are pursuing drugs to combat PKC theta (cancer again) and PKC epsilon (Alzheimer’s).
In the world of biotech drug development, success has been, and continues to be, a very elusive dream – not unlike the discovery of a multimillion ounce gold resource. And PharmaGap is not the only company in the PKC arena. But with some of Canada’s best and brightest working on the leading edge, PharmaGap merits serious attention.
From its inception in 1999, PharmaGap has undertaken the scientific research and development work required to understand the many ways in which the 11 unique isoforms making up the family of proteins named Protein Kinase C (PKC) act within the human body in relation to human diseases. PharmaGap has developed proprietary computer-based methodologies that provide the ability to design selective inhibitors for PKC isoforms. The importance of the PKC family is well known in the medical and pharmaceutical industry and has been and continues to be the subject of significant preclinical and clinical research.
PKCs are associated with a range of human disease conditions, including not only cancer, but also metabolic diseases such as diabetes (PKC beta, epsilon), cardiac disease (PKC delta), Alzheimer's (PKC epsilon) and neurological disease (PKC gamma). In addition to its compounds targeting PKC alpha and theta, PharmaGap has designed, and is currently optimizing prior to synthesis and testing, an inhibitor for PKC epsilon.
April 17th News Excerpt
You can grab the full news release at www.stockhouse.com or any service you typically use, but here is the most important excerpt: The other control groups they used were: saline only, PhG (their drug) along with Chemo, and Chemo Only. The control group with their drug only PhG is referenced below - this is what killed the tumours
Breast cancer metastatic model
In this model, human breast cancer of the type Estrogen Receptor negative, which as a group represents the 30 per cent of breast cancers which are not currently treatable by available drug therapies, were implanted into the bloodstream and provided with a seven-day period to allow tumours to form. The type of cancer cells implanted is known to be highly invasive to the lungs, within a three- to five-day period following implantation. Following this establishment period of seven days, the treatment regime began in the eight groups of five mice.
In the group of five mice receiving PhG-alpha-1 at the dose of one milligram per kilogram of body weight, four of five (80 per cent) when euthanized at the end of the trial period were observed to be tumour-free on postmortem examination, with no effect on other organs. The remaining mouse had developed a single small, friable (easily broken down) tumour. In the two control groups (saline and chemotherapy alone), nine of 10 (90 per cent) developed tumours, with only one surviving to the end of the trial and with ancillary organ damage to some degree. For all other treatment groups, 22 of 25 (88 per cent) developed tumours, and none survived to the end of the trial, again exhibiting ancillary organ damage.
Ya a cure for cancer should would be great
whatever works, hope its the miracle cure
HUGE got all freebees yet as I trade this thing to death or launch to a miracle
Your a closet believer, this could be huge!
back in at .36
looks alive to me
Good one we will let John start the bidding
Between you T, and John. That shouldn't be a prob.
Alot of paper has been flushed into the market now and it will take millions of traded shares to bring this back to life
basically all the reasons my wife is riding her now free shares
hope he is not just pumping in public so his subscribers can get out
Pullback from a 450% Run 10 days Ago, the GAP story is Fascinating
Major Implications For Cancer ?
Microcaps (and penny stocks in general) can be both exciting and very frustrating. While volatility seems to be the norm, every decade we also see something astonishing come out of a few of these small companies. Astonishing may mean a stock like Bre-X that starts out near 0.40 and ends up near $300 before someone is thrown out of a helicopter. Or it may mean honest discoveries like Diamet that went from penny status to a diamond mine worth Billions, Diamond Fields massive nickel discovery at Voisey Bay, Arequipa's gold discovery and buyout by Barrick in Peru. There are several more like this and likewise for the oil & gas industry.
The interesting part of all this, is that these are resource stocks. Success stories in the tech space we watched in 1999 and 2000 thanks to irrational exhuberance and an overheated market - although some amazing stories came out of that era like Research in Motion and their Blackberry which drove the price from under $3 to well over $100 now.
While all this is the stuff dreams are made of from a financial point of view, they did nothing to contribute to the betterment of mankind. Unless of course you count the Blackberry which for some is as critical as an oxygen tank attached to an emphysema patient ! And by betterment I mean contributing to our quality of life, not buying a new Lexus because your stock just went from a dollar to twenty.
So that brings us to the Biotech sector. From a microcap perspective, its often very difficult for these little companies to raise capital and as such, you rarely hear about major discoveries coming out of this field of science. Thanks to heavy regulation, they can take years to mature and if something significant does comes along, the majors typically buy them out before a massive double digit run in share price can occur. I've been buying penny stocks for over twenty years now and while I'm sure I've forgotten something by now, I cannot remember a huge biotech story coming out of Canada (from a small or microcap perspective).
That brings us to PharmaGap (GAP.V $0.35)
www.pharmagap.com
First and foremost. My introduction above is not meant to indicate this is the next retirement income plan. It simply demonstrates the potential of microcap stocks and proves that while its very difficult hitting a home run on these stocks, its also possible.
I typically don't bother with biotechs because very few ever amount to anything before they run out of cash, and I don't have the patience to sit on a penny stock for three years waiting for a miracle to occur. In addition to this, you need a very strong stomach for volatility. Pharmagap is a perfect example as it gained 450% in 1 day after running from $0.20 to $1.10 on April 17th as millions of dollars worth of buying piled into this stock. Yet you see the price now.
The morning of the 17th we sent GAP to our paid subscribers once a very important news release was issued. While everyone watched this incredible rise in price, we've now watched that same stock get destroyed from its high. The problem can be summed up in one word... traders. A tremendous amount of buying came into this company on news I will highlight below but with little happening in this market for the technical traders, it didn't take long for the gains and volume to pop onto the TSX.V radar. If momentum is positive, the trend remains intact. If the tide turns, so does the share price. As the price fell, the traders moved out and those who bought for a longer term hold likely second guessed their decision and cut a quick loss. People typically read into a trading pattern following news and use this to try and determine whether their assesment was right or wrong.
What all this "may" have done, is create a new opportunity for others. Had this stock not fallen back so hard I would have waited a long time before introducing it to free subscribers or on Stockhouse - the risks were just way too high. Even right now, the risks may be very high. This stock rarely ever traded prior to this news and the last few financings were done at $0.06 by the CEO. Unfortunately this company was so low on anyone's radar that the price and volume were ridiculously low.
World Class Management & Researchers
It was also this very same reason I (at first) totally ignored the news release I saw on April 17th. I honestly thought that in typical penny stock fashion it was nothing more than hype to help some slimey promoter get his stock off. It wasn't until I quickly did more research and found out this company was a spinoff from the National Research Council of Canada (Canada's premier biological research organization) and the scientists behind this company were (surprisingly) amongst the best in their field. In addition to the scientific side, they have tremendous talent on the other side of the equation. As an example, their Chief Operating Officer was Vice President, Investment Banking with Credit Suisse First Boston in New York and TD Securities in New York and Toronto. This quickly ruled out the slimey promoter theory and immediately provided credibility.
Why the Excitement ?
In early trials on mice (announced April 17th), they treated a control group that resulted in tumours disappearing in 4 of the 5 with the 5th having enough damage to the tumour it could be easily broken down. In all other control groups (including chemo), there was no impact and the tumours would have resulted in death. What was amazing, this result was on a cancer type that accounts for 30% of all breast cancer with NO known treatment. Basically it moves so fact (typically to the lungs) that the patience dies in a short period of time.
In addition to this, they had excellent results on colon cancer treatment as well. Its this impact on the breast cancer tumours that is amazing however. If this continues and can be proven safe for humans, it "may" become a major breakthrough in cancer treatment.
The Memorial Sloan-Kettering Cancer Institute New York
www.mskcc.org
In an independent validation of GAP's potential, the company announced on April 24th they were partnering with The Memorial Sloan-Kettering Cancer Institute of New York - one of the world's premier cancer centers. This is over and above the research being done on breast cancer mentioned above. The Institute will be working with the company to develop a selective inhibitor of PKC theta for use in treatment of sarcomas, cancers of supportive and connective tissue (that is bone, cartilage, fat, muscle and blood vessels).
Said Sloan-Kettering's Dr. Schwartz: "I look forward to continuing my collaboration with PharmaGap for this exciting new compound, as it holds the promise of new treatment alternatives in the future for sarcoma patients. Selectively targeting PKC theta may provide therapeutic benefits not provided by current treatments."
Protein Kinase C (PKC)
Over the ages, experimental biology has used two research approaches, in vitro (within the glass) and in vivo (within the living). Typically drug candidate selection and experimentation occur at the simpler "test tube" level. The final proving ground is at the living level of Mice and Men and clinical trials.
Enter the Brave New World of computer biologists and their approach - in silico (within the silicon chip) where computer simulations model natural and laboratory processes.
PharmaGap is on the leading edge of in silico drug development. Their primary candidate, PhG-alpha-1, is one of a new breed of targeted cancer drugs that largely confine their activities to the tumor cells. Consider the huge benefit of hitting the target with a bullet compared to standard "shotgun" chemotherapies, where the hope is that they kill the cancer before they kill the patient.
PharmaGap's current research centers on a family of naturally occurring enzymes known as Protein Kinase C (PKC). These enzymes have diverse and important effects on our cells. They must be highly regulated or controlled to maintain certain aspects of that delicate balance known as health. Numerous cancers involve over expression of PKC - too much of a good thing.
One member of the PKC family is especially noteworthy in the cancer realm - PKC alpha, which is the selected target for the PhG-alpha-1 drug.
Besides targeting, another very positive angle for PhG-alpha-1 relates to an unfortunate characteristic of many cases of cancer - Multi Drug Resistance or MDR. Special proteins embedded in the cell membrane, called MDR pumps, actually "spit out" any chemotherapy drug that enters the cancer cell - great for survival of the cancer cell, but certainly not the patient. There is a strong correlation between high levels of PKC and MDR activity. Perhaps PhG-alpha-1 could be a stone that kills two birds at once. The strategy of combining PhG-alpha-1 with other chemotherapeutic agents may open up a wider range of possibilities.
The area of PKC research is receiving much attention these days, and for good reason. Other members of the PKC family are implicated in such disorders as diabetes, cardiac disease, and Alzheimer's. PhamaGap recently announced they are pursuing drugs to combat PKC theta (cancer again) and PKC epsilon (Alzheimer's).
In the world of biotech drug development, success has been, and continues to be, a very elusive dream - not unlike the discovery of a multimillion ounce gold resource. And PharmaGap is not the only company in the PKC arena. But with some of Canada's best and brightest working on the leading edge, PharmaGap merits serious attention.
From its inception in 1999, PharmaGap has undertaken the scientific research and development work required to understand the many ways in which the 11 unique isoforms making up the family of proteins named Protein Kinase C (PKC) act within the human body in relation to human diseases. PharmaGap has developed proprietary computer-based methodologies that provide the ability to design selective inhibitors for PKC isoforms.
The importance of the PKC family is well known in the medical and pharmaceutical industry and has been and continues to be the subject of significant preclinical and clinical research.
PKCs are associated with a range of human disease conditions, including not only cancer, but also metabolic diseases such as diabetes (PKC beta, epsilon), cardiac disease (PKC delta), Alzheimer's (PKC epsilon) and neurological disease (PKC gamma). In addition to its compounds targeting PKC alpha and theta, PharmaGap has designed, and is currently optimizing prior to synthesis and testing, an inhibitor for PKC epsilon.
April 17th News Excerpt
You can grab the full news release at www.stockhouse.com or any service you typically use, but here is the most important excerpt: The other control groups they used were: saline only, PhG (their drug) along with Chemo, and Chemo Only. The control group with their drug only PhG is referenced below - this is what killed the tumours
Breast cancer metastatic model
In this model, human breast cancer of the type Estrogen Receptor negative, which as a group represents the 30 per cent of breast cancers which are not currently treatable by available drug therapies, were implanted into the bloodstream and provided with a seven-day period to allow tumours to form. The type of cancer cells implanted is known to be highly invasive to the lungs, within a three- to five-day period following implantation. Following this establishment period of seven days, the treatment regime began in the eight groups of five mice.
In the group of five mice receiving PhG-alpha-1 at the dose of one milligram per kilogram of body weight, four of five (80 per cent) when euthanized at the end of the trial period were observed to be tumour-free on postmortem examination, with no effect on other organs. The remaining mouse had developed a single small, friable (easily broken down) tumour. In the two control groups (saline and chemotherapy alone), nine of 10 (90 per cent) developed tumours, with only one surviving to the end of the trial and with ancillary organ damage to some degree. For all other treatment groups, 22 of 25 (88 per cent) developed tumours, and none survived to the end of the trial, again exhibiting ancillary organ damage.
who knows alot paper has been dumped here
Placement then announcement.
The GAP is leaving quite a paper trail behind
PharmaGap compound tests selectivity to PKC theta
2008-04-24 07:59 MT - News Release
Mr. Robert McInnis reports
PHARMAGAP REPORTS POSITIVE EARLY RESULTS FOR NEXT DRUG COMPOUND
PharmaGap Inc. has successfully completed in vitro or "bench" testing of a new compound designed to be a selective inhibitor of Protein Kinase C Theta (PKC theta), showing indication of selectivity to and inhibition of PKC theta. This new compound follows on the successful completion of the research and development phase of preclinical testing for the company's selective inhibitor of PKC alpha, PhG-alpha-1, announced last week.
PKC theta was selected as the target for the company's next compound on the basis of interest expressed by Dr. Gary Schwartz of Memorial Sloan-Kettering Cancer Institute New York in working with the company to develop a selective inhibitor of PKC theta for use in treatment of sarcomas, cancers of supportive and connective tissue (that is bone, cartilage, fat, muscle and blood vessels). Dr. Schwartz is chief of Sloan Kettering's Melanoma and Sarcoma service. In vitro testing of the new PKC theta inhibitor will continue at PharmaGap and in Dr. Schwartz's laboratories at Sloan-Kettering.
Said Sloan-Kettering's Dr. Schwartz: "I look forward to continuing my collaboration with PharmaGap for this exciting new compound, as it holds the promise of new treatment alternatives in the future for sarcoma patients. Selectively targeting PKC theta may provide therapeutic benefits not provided by current treatments."
This initial positive in vitro test result for the new PKC theta inhibitor also demonstrates the company's ability to apply its knowledge base and proprietary techniques to develop a rich pipeline of peptide drug compounds targeting the PKC family of proteins. Proprietary analytical tools provide the Company with the ability to design and test drug designs inside the computer, allowing for the optimization of the compound design prior to synthesis and commencement of laboratory testing.
From its inception, the company has undertaken the scientific research and development work required to understand the many ways in which the 11 unique isoforms making up the family of proteins named Protein Kinase C act within the human body in relation to human diseases. PharmaGap has developed proprietary computer-based methodologies that provide the ability to design selective inhibitors for PKC isoforms. The importance of the PKC family is well known in the medical and pharmaceutical industry and has been and continues to be the subject of significant preclinical and clinical research.
PKCs are associated with a range of human disease conditions, including not only cancer, but also metabolic diseases such as diabetes (PKC beta, epsilon), cardiac disease (PKC delta), Alzheimer's (PKC epsilon) and neurological disease (PKC gamma). In addition to its compounds targeting PKC alpha and theta, PharmaGap has designed, and is currently optimizing prior to synthesis and testing, an inhibitor for PKC epsilon.
still negative out there.needs more wacking as too much cheap paper flying around here
hmm financials?
that would be another 10 million pp at .50
well there negative 5 mil so money is needed badly
a ten bagger for the warrants would ice the cake!
weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee
i cant imagine anyone in their right mind selling there .125 shares for anything less than .75 :)
alot of loosey goosey shares here it seems
dont be like that! lol
np hopefully that chart looks better in a year
PharmaGap (TSX-V:GAP)
PharmaGap is a biotechnology company with a core focus on developing novel therapeutic compounds for the treatment of cancer. Its shares soared as much as 500% on April 17 before pulled back some portion, following encouraging results from animal studies showing that its lead cancer drug, PhG-alpha-1, is effective against breast and colon cancer. This corresponds to last year's laboratory tests which also showed positive results. More pre-clinical studies and clinical trials are needed, but the hope is raised that the company will successfully make its first cancer drug into the marketplace. Liquidity appears to be a major hurdle, given the excessive short-term liabilities and consistent negative operation cash flows sitting on its balance sheet; however, management is moving in the right direction to get partners to fund its operations. As such the stock remains highly speculative but could offer good upside potentials.
http://www.maybachfinancial.com/articles/index.php?id=21&newsID=45
back down to 10 cents?
sold .44 profit is profit thanks for the chart
Our first recommendation is our top pick involving a sector that’s bigger than the Internet and a company that may be poised to take over that sector. Imagine Google’s market share over their sector : the Internet. Now imagine a small unknown company that may take over their sector – a sector even bigger than the internet. Sign up now to unveil this hidden secret Wall Street does not want you to know.
http://www.maybachfinancial.com/articles/index.php?id=6&name=Register
New Analyst Insight on PHARMAGAP INC, FORTIS INC, and POTASH ONE INC
April 17, 2008 1:12 PM EDT
DUBAI, UNITED ARAB EMIRATES -- (MARKET WIRE) -- 04/17/08 -- MaybachFinancial.com is one of the fastest growing independent and unbiased research firms in the world. Investors wanting to know the truth about investing and how to consistently profit from whatever the markets throw our way should sign up to www.maybachfinancial.com for a free trial subscription. Through our numerous partnerships with many of the top investment minds in the world, we provide research on every company making a move in the markets. Investors seeking genuine analyst opinions on their investments for PHARMAGAP INC (TSX-V: GAP), FORTIS INC (TSX: FTS), and POTASH ONE INC (TSX-V: KCL) should take this opportunity to get free in-depth research by becoming a member today. Our initial coverage of any company will include research in the following areas:
-- Margin changes, specifically operating, gross, and then net
-- The pace and quality of top line growth
-- The ability to generate cash
-- The pace and quality of the bottom line growth
-- Market share gains
-- Innovation/pipeline
-- Corporate governance
-- Management's ability to operate in unfavorable environments
-- The ability of management to control acquisitive growth and achieve
accretive results
PHARMAGAP INC rose over an astounding 627% in afternoon trades. Hear what our analysts think by signing up to www.maybachfinancial.com for your free analyst report on PHARMAGAP INC as share value has increased dramatically today. Our research team will be evaluating the company's progress to determine the price level for investors.
FORTIS INC remained relatively unchanged in afternoon trades today. After climbing to a high of $29.94 recently, share value appears to be correcting itself. Sign up to gain insight from our analyst review for this Company at www.maybachfinancial.com or follow this link: http://www.maybachfinancial.com/articles/?id=6&name=Register
POTASH ONE INC fell over 4.5% in afternoon trades. Like many companies over the past 52-weeks, POTASH ONE INC has experienced an overall roller coaster ride since last year, dipping as low as $0.72 and rising to highs of $5. We will have an analyst review on this company for investors seeking answers which will be posted in the member's area of www.maybachfinancial.com under "Analyst Reviews."
Maybe not until another placement is done, could be an opportunity here for a bit.
Thanks. I'll look into it. Foriegn territory for me to.
More KA-BOOOOOOOOOOOOOOOOOOOOOOOOMS then
sure or 5 - 10 cents (kidding lol)... seriously though the news is fantastic!
to be honest Arc I dont really have a feel for biotech. I got involved last year when I saw the insider ownership and the credentials of the people involved.
So what's the story here? 5 - 10 bucks?
Followers
|
5
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
140
|
Created
|
05/07/07
|
Type
|
Free
|
Moderators |
PharmaGap, Inc (TSX:GAP)
OTC.BB.PHRGF
Address:
100 Sussex Drive
Ottawa, Ontario
K1A 0R6 CANADA
613.998.3400
613.998.3399 (fax)
General inquiries: info@pharmagap.com
Employment inquiries: hr@pharmagap.com
PharmaGap is pursuing pre-clinical development of its lead drug candidate, GAP-107B8, for use in treating cancer. GAP-107B8 selectively targets Protein Kinase C (PKC), a validated target for potentially treating certain types and stages of cancer. GAP-107B8’s compelling bioactivity, efficacy and excellent safety profile has been demonstrated in vitro and in animal models. GAP-107B8 has been developed by way of computer assisted rational drug design.
PharmaGap’s researchers have deep knowledge of cell signaling pathways involved in the onset of cancer, particularly those controlled by the PKC family. Work is also being pursued developing a pipeline of drug modulators targeting PKC isoforms important in other disease conditions, such as heart disease and diabetes.
PharmaGap’s business model strategy is to out-license its drug compounds targeting PKC prior to commencement of later-stage clinical trials in humans. Management and the board are pursuing this strategy to maximize sustainable value for shareholders. PharmaGap shares trade on Toronto’s TSX-Venture Exchange.
Founded in 1999, PharmaGap is a spin-out from the National Research Council of Canada, Canada’s premier biological research organization. The Company’s development activities take place in labs and offices located in Ottawa, Ontario, Canada.
Management: http://www.pharmagap.com/company_overview/management.html
Drug Development: http://www.pharmagap.com/drug_development/index.html
Recent News:
http://www.pharmagap.com/news/index.html
http://cxa.marketwatch.com/TSX/en/Market/news.aspx?symb=GAP&sid=1122071
Links of importance for those that trade Canadian stocks:
Sedar http://www.sedar.com/homepage_en.htm
TMX. http://www.tmx.com/
TMXmoney http://www.tmxmoney.com/en/index.html
CNW Group Newswire http://www.cnxmarketlink.com/en/index.cgi
Canadian Insider
http://canadianinsider.com/coReport/allTransactions.php?ticker=sss
Currency Converter:
http://www.bankofcanada.ca/en/rates/converter.html
CHART is for Canadian ticker. Remember to adjust for exchange rate.
Currency Converter: http://www.bankofcanada.ca/en/rates/converter.html
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |